Athena Investments A/S
19.1.2021 13:54:27 CET | Globenewswire | Press release
Company Announcement No. 02/2021
Copenhagen, 19 January 2021
Fidim S.r.l. (“Fidim”) has acquired more than 90% of the total share capital and voting rights of Athena Investments A/S (“Athena”) following the completion of its voluntary public cash offer dated 19 October 2020 (see Company Announcement No. 22/2020).
Consequently, Fidim is entitled to carry out a compulsory acquisition of the shares held by the remaining shareholders of Athena.
Simultaneously with the initiation of the compulsory acquisition process, an application is made to Nasdaq Copenhagen A/S (“Nasdaq Copenhagen”) with a request to remove Athena’s shares (ISIN DK0010240514) from trading and official listing at Nasdaq Copenhagen.
Reference is made to the attached notice from Fidim for further information on the compulsory acquisition to the minority shareholders of Athena.
The Board of Directors
Contact:
Peter Høstgaard-Jensen, Chairman of the Board of Directors, Tel: +45 40 10 88 71
Francesco Vittori, CEO, Tel.: +45 33 36 42 02
Attachments
- 2102_Notice_compulsory_acquisition_and_delisting_request_19_01_21_UK
- Notice of compulsory acquistion (UK) - Athena Investments
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Biogen Inc.28.3.2026 20:00:00 CET | Press release
Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity
MoonLake Immunotherapeutics AG28.3.2026 20:00:00 CET | Press release
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Sanofi Winthrop Industrie28.3.2026 16:00:00 CET | Press release
Press Release: AAD: new results from Sanofi's amlitelimab phase 3 studies in atopic dermatitis presented in late-breaking research session
Rocket Lab Corporation28.3.2026 11:39:53 CET | Press release
Rocket Lab Successfully Launches 85th Mission and First Dedicated Launch for European Space Agency
Vivoryon Therapeutics N.V.28.3.2026 07:00:00 CET | Press release
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
